Whether it is appropriate, and how it should be used and monitored, must be decided by a qualified physician
Emerging studies are exploring the potential of GLP-1-based therapies in diverse populations and comorbidities, such as patients with type 2 diabetes or cardiovascular diseases
Several indirect mechanisms may explain why some individuals notice changes in urine odour whilst taking Wegovy, most of which relate to the metabolic and dietary changes accompanying significant weight loss rather than the medication itself
For this reason, semaglutide has been employed by health care providers for over 15 years in the management of type 2 diabetes
This compounded pathway is legal, regulated, and accessible through a qualified provider partnershipoffering an alternative to branded costs without compromising prescription oversight or clinical accountability
The trial aimed to evaluate if semaglutide, a once-weekly GLP-1 receptor agonist, would mitigate kidney outcomes and death